Efficacy and safety of Buzhong Yiqi Decoction in improving cancer-related fatigue and immunity of cervical carcinoma patients

A protocol of randomized controlled trial

Juan Hu, MBa, Xia Li, MBb, Yanping Fang, MBb, Jin Peng, MBa,*

Abstract

Background: Cancer-related fatigue (CRF) is essentially universal in cervical carcinoma patients. It develops rapidly, with physical and mental manifestations including generalized weakness, diminished concentration or attention, and it has a negative impact in overall quality of life. Buzhong Yiqi Decoction (BYD), a classical Chinese medical prescription, could be used for allergic rhinitis, gut microbiota disorders, and chronic obstructive pulmonary disease. We preliminarily found that BYD could relieve CRF in cervical carcinoma patients. However, there are few trials on whether BYD could relieve CRF and improve immunity in cervical carcinoma patients.

Methods: This is a double-blinded, randomized, controlled clinical trial. From December 1, 2021 to May 31, 2022, cervical carcinoma patients with CRF will be assessed for randomization into treatment group (BYD) and control group (BYD simulation) in a 1:1 ratio. The outcomes are cancer fatigue scale, self-rating anxiety scales, self-rating depression scales, Pittsburgh sleep quality index, and immunity index (CD3+, CD4+, and CD8+) before and after the treatment. Statistical analysis will be performed using SPSS v22.0 software.

Results and conclusions: The study will clarify the efficacy and safety of BYD in improving CRF and immunity in cervical carcinoma patients.

Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/QFNMD.

Abbreviations: BYD = Buzhong Yiqi Decoction, CRF = cancer related fatigue, TCM = traditional Chinese medicine.

Keywords: Buzhong Yiqi Decoction, cancer related fatigue, cervical carcinoma, Chinese medicine, RCT

1. Introduction

Cervical carcinoma, a malignant tumor that develops in the cervix, is mainly related to long-term infection. It is a common malignant tumor all over the world, with a high incidence, which has seriously affected women’s physical and mental health.[1,2] In recent years, chemotherapy has gradually become one of prior treatment methods for cervical carcinoma.[3–5] It has been reported that low-dose chemotherapeutics could increase the sensitivity of radiotherapy in cervical carcinoma patients. With the continuous development of concurrent radiotherapy and chemotherapy, the efficacy and local control rate of radiotherapy have gradually increased, and the recurrence rate has initially decreased. Also, a large number of clinical studies have shown that concurrent radiotherapy and chemotherapy can significantly improve the survival rate of patients with advanced cervical carcinoma.[6,7]

Fatigue is one of the most common side effects of malignant tumor and its treatment, known as cancer related fatigue (CRF). It’s a subjective experience self-reported symptoms.[6,7] In recent years, CRF has gradually received clinical attention and intervention. CRF is widespread in cancer patients, and it is even a more common side effect in patients receiving chemotherapy and radiotherapy. It’s estimated that the prevalence ranges from 25% to 99% in cancer patients after treatment.[10,11] In cervical carcinoma patients, CRF was reported by 23% of long-term survivors at a mean of 11 years after treatment, and 28% in patients with chemoradiation.[12] CRF develops rapidly, with physical and mental manifestations including generalized weakness, diminished concentration or attention, and it has a negative impact in overall quality of life.
A variety of interventions have been used for CRF, including physical activity, psychosocial and pharmacological interventions, yet with limited or unclear feasibility and efficacy. Traditional Chinese medicine (TCM) could control the development of cervical carcinoma. As an adjuvant treatment, it could also reduce adverse reactions and side effects of radiotherapy and chemotherapy, improve the long-term curative effect and the quality of life. Buzhong Yiqi Decoction (BYD), a traditional Chinese prescription, is composed of Huangqi (Astragalus membranaceus), Baizhu (Atractylodes atractylodes), Chenpi (Pericarpium citri reticulatae), Shengma (Rhizoma cimicifugae), Chaihu (Radix bupleuri), Rensheng (Ginseng), Gancao (Liquorice), and Danggui (Radix Angelicae Sinensis). Clinically, BYD could be used for allergic rhinitis, gut microbiota disorders, and chronic obstructive pulmonary disease.

We preliminarily found that BYD could be used for CRF in cervical carcinoma patients. However, few trials have been reported on whether BYD could reduce CRF in cervical carcinoma patients. In this study, we try to conduct a randomized controlled trial to clarify the efficacy and safety of BYD in relieving CRF and improving immunity in cervical carcinoma patients.

2. Methods

2.1. Trial design

This is a randomized, controlled clinical trial, and it has been approved by the Ethics Committee of the Hospital Affiliated to Jianghan University. The study will be carried out in accordance with the Declaration of Helsinki. It conforms to the SPIRIT 2013 Statement, and the results will be reported according to the CONSORT Statement extension for trials (Fig. 1). This study protocol has been registered with Open science framework Registry platform (OSF Registration number: DOI 10.17605/OSF.IO/QFNMD).

2.2. Participants

2.2.1. Recruitment. From December 1, 2021 to May 31, 2022, cervical carcinoma patients diagnosed with CRF will be assessed for eligibility. Before randomization, all patients will sign a written informed consent, and they can freely choose whether to discontinue the trial at any time.

2.2.2. Inclusion and exclusion criteria. Patients will be included if they meet the following criteria:

1) primary diagnosis of cervical carcinoma in stage Ib–IVa;
2) complained of fatigue and a diagnosis with CRF;
3) aging from 18 to 70;
4) with signed informed consent.

Patients will be excluded if they are:

1) complicated with other malignant tumors;
2) received surgery before;
3) with severe abnormal liver or kidney function;
4) history of allergy to BYD.

2.3. Randomization

For allocation, patients will be simply assigned into treatment group (BYD) and control group (BYD simulation) in a 1:1 ratio. The randomization sequence will be generated by a statistician uninvolved in the statistical analysis. The random numbers will be placed in opaque, sealed envelopes and kept in a safe place. Each participant had a 50% probability of receiving each intervention upon selection.

2.4. Blinding

This is a double blinded, and dummy study. The physician, patients, and assessors will all be blinded to the allocation. To maintain blindness, the decoction and simulations will be provided as granules. The BYD-simulations are in the same appearance, package, color, taste, and administration with BYD.

2.5. Interventions

Patients diagnosed with CRF in the treatment group will be treated with traditional Chinese prescription of BYD as granules, including Huangqi (A membranaceus) 15g, Baizhu (A atractylodes) 10g, Chenpi (P citri reticulatae) 10g, Shengma (R cimicifugae) 6g, Chaihu (R bupleuri) 12g, Dangshen (Radix codonopsis pilosulas) 15g, Gancao (Liquorice) 15g, and Danggui (R Angelicae Sinensis) 6g. The granules will be provided by the Beijing Tcmages Pharmaceutical Co., Ltd., and they will be orally taken by dissolving in 50mL warm water, twice a day, for 14 days. While in the control group, BYD simulations made of amylum will be applied for patients with the same administration method.

2.6. Outcome variables

The primary outcome is the change of fatigue scores measured by cancer fatigue scale before and after the treatment. The secondary outcomes are self-rating anxiety scales, self-rating depression scales, Pittsburgh sleep quality index, and immunity index (CD3+, CD4+, and CD8+) before and after the treatment. Blood routine, liver and kidney function, coagulation, and adverse events will also be recorded.

2.7. Sample size

In our preliminary study, the change of cancer fatigue scale scores in the treatment group was $6.65 \pm 2.12$, while $3.5 \pm 1.53$ in the control group. Considering a 2-sided $t$ test, with 5% type I error.
at 80% power, and a potential dropout of 10%, the required total sample size will be 110.

2.8. Statistical analysis

Statistical analysis will be performed using SPSS v22.0 software. The measurement data is expressed as mean±standard deviation, and Student t test, Wilcoxon rank-sum test, or Mann–Whitney U test after normality and homogeneity test. The count data is expressed as percentage (%) and χ² test will be applied. P < .05 is considered statistically significant.

3. Discussions

Cancer-related fatigue (CRF) is essentially universal in patients receiving cancer treatment other than surgery, and it can be influenced by many factors, such as medications, pain, sleeplessness, and depression, etc. It develops rapidly, and patients may be complained with generalized weakness, diminished concentration or attention. At present, the understanding of the etiology and pathogenesis of CRF is still limited, and there are only a few limited or unclear treatment methods. Therefore, a treatment with high practicability, safe and effective treatment needs to be further studied.

As an adjuvant treatment, TCM could reduce adverse effects to improve the quality of life. BYD, a traditional Chinese prescription, could regulate immune function, and act as an effective biological regulator to promote protein synthesis and energy metabolism. Clinically, BYD could be used for allergic rhinitis, gut microbiota disorders, and chronic obstructive pulmonary disease. The symptoms of CRF are similar to Qi deficiency in TCM, which can be treated by BYD. Therefore, in this study, we try to conduct a randomized controlled trial to clarify the efficacy and safety of BYD in relieving CRF and improving immunity in cervical carcinoma patients.

Yet, it has to be claimed some limitations in this protocol. First, several outcomes are measured by subjective scale, and there might be some certain biases. Second, the recruitment of patients is single and limited in Wuhan, which may affect the conclusions to some extent.

Author contributions

Conceptualization: Jin Peng.
Data collection: Juan Hu and Xia Li.
Funding acquisition: Jin Peng.
Investigation: Juan Hu.
Protocol design: Juan Hu and Xia Li.
Resources: Xia Li.
Software operating: Xia Li and Yanping Fang.
Supervision: Yanping Fang and Jin Peng.
Writing – original draft: Juan Hu and Xia Li.
Writing – review and editing: Juan Hu and Jin Peng.

References

[1] Krieger N, Wright E, Chen JT, Waterman PD, Huntley ER, Arcaya M. Cancer stage at diagnosis, historical redlining, and current neighborhood characteristics: breast, cervical, lung, and colorectal cancers, Massachusetts, 2001–2015. Am J Epidemiol 2020;189:1065–75.
[2] Li XX, Lin TT, Liu B, Wei W. Diagnosis of cervical cancer with parametral invasion on whole-tumor dynamic contrast-enhanced magnetic resonance imaging combined with whole-lesion texture analysis based on T2-weighted images. Front Bioeng Biotechnol 2020;8:6590.
[3] Shao C, He J, Stein K, Keele S. Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study. Curr Med Res Opin 2020;36:1187–94.
[4] Yang SL, Chen L, He Y, Zhao H, Wu YM. Effect of neoadjuvant chemotherapy followed by surgery for FIGO stage I–II cervical cancer: a meta-analysis. J Int Med Res 2020;48:300065520945507.
[5] Zhang F, Yao M, Lin Z, et al. The effects of preoperative oral carbohydrate on frequency of T and NK cells in patients with cervical cancer treated using neoadjuvant chemotherapy and surgery: a prospective cohort study. BioMed Res Int 2020;2020:2101480.
[6] Yu H, Zhang L, Li D, et al. Postoperative adjuvant chemotherapy combined with intravacucial brachytherapy achieved the equivalent survival compared with concurrent chemoradiotherapy in cervical cancer patients with intermediate-risk. Jpn J Clin Oncol 2019;49:714–8.
[7] Chaudary N, Hill RP, Stulik L, Milosevic M. The oral CXCR4 inhibitor X4-136 improves tumor control and reduces toxicity in cervical cancer treated with radiation therapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2021;110:1117–24.
[8] Obama K, Maru M, Maeda R, Kubota T. Cancer-related fatigue and physical activity among premenopausal cervical and endometrial cancer survivors in Japan. J Med Dent Sci 2015;62:57–68.
[9] Gernier F, Joly F, Klein D, Mercier M, Velten M, Licia I. Cancer-related fatigue among long-term survivors of breast, cervical, and colorectal cancer; a French registry-based controlled study. Support Care Cancer 2020;28:5839–49.
[10] Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004;40–50.
[11] Bower JE. Cancer-related fatigue – mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014;11:597–609.
[12] Steen R, Dahl AA, Hess SL, Kserud CE. A study of chronic fatigue in Norwegian cervical cancer survivors. Gynecol Oncol 2017;146:630–5.
[13] Yi-Ling F, Qing M, Xing L, et al. [Systematic review and Meta-analysis on efficacy and safety of Buzhong Yiqi Decoction for stable chronic obstructive pulmonary disease]. Zhongguo Zhong Yao Za Zhi = China Journal of Chinese materia medica 2020;45:3544–55.
[14] Feng L, Lin L, Wang S, et al. Clinical practice guidelines for the treatment of allergic rhinitis in children with traditional Chinese medicine. Anat Rec (Hoboken) 2021;304:2592–604.
[15] Ni Z, Cheng W, Ding J, et al. Impact of Buzhong Yiqi prescription on the gut microbiota of patients with obesity manifesting polycystic ovarian syndrome. Evid Based Complement Alternat Med 2021;2021:6671367.
[16] Colomo N, Olveira C, Hernandez-Pedrosa J, et al. Validity of self-reporting screening scales for the diagnosis of depression and anxiety in adult patients with bronchiectasis. Arch Bronconeumol (Engl Ed) 2021;57:179–85.
[17] Amiris K, Omerovic E, Danneskiold-Samsoe B, Bliddal H, Waehrens EE. The validity of self-reporting depression scales in patients with chronic widespread pain: a Rasch analysis of the Major Depression Inventory. Scand J Rheumatol 2016;45:236–46.
[18] Li L, Sheehan CM, Thompson MS. Measurement invariance and sleep quality differences between men and women in the Pittsburgh Sleep Quality Index. J Clin Sleep Med 2019;15:1769–76.
[19] Dickinson K, Lim A, Kupzyk KA. Demographic, symptom, and lifestyle factors associated with cancer-related fatigue in men with prostate cancer. Oncol Nurs Forum 2021;48:423–30.
[20] Gupta A, Hussain SM, Nayyar HK, Sonthwal N, Manaktala R, Chaturvedi H. Perception, magnitude, and implications of cancer-related fatigue in breast cancer survivors: study from a developing country. J Cancer Res Ther 2021;17:998–1002.